Sarah Esther Conway

Sarah Esther Conway

Auto-generated profile, based on publicly available information

Sarah Esther Conway

Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
SCSarah E. Conway
Sarah E. Conway
BHBrian C. Healy
Brian C. Healy
JZJonathan Zurawski
Jonathan Zurawski
CSChristopher Severson
Christopher Severson
TKTamara Kaplan
Tamara Kaplan
MHMaria K. Houtchens
Maria K. Houtchens

11 August 2022 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
SCSarah E Conway
Sarah E Conway
DPDanielle Kei A Pua
Danielle Kei A Pua
KHKathryn B Holroyd
Kathryn B Holroyd
KGKristin Galetta
Kristin Galetta
SBShamik Bhattacharyya
Shamik Bhattacharyya
Background: There is concern that immune checkpoint inhibitors (ICPIs) can provoke relapses in people with multiple sclerosis (pwMS). Objective: Analyze outcomes of pwMS who received ICPI treatment for malignancy. Methods: We electronically identified pwMS who received ICPI treatment at Mass General Brigham hospital system. We retrospectively obtained information about patients’ MS, cancer, treatment, and outcomes. Results: Sixteen patients were identified with an average (standard deviation (SD)) age of 67.4 (11.9) years. Eleven (68.8%) had no relapses since MS diagnosis. None had MS relapses after ICPI treatment or new MS lesions. Conclusion: ICPI use was not associated with increased clinical disease activity in this cohort of older patients with inactive MS.

10 December 2024 in Neurology
Verified
Journal Article
Closed access
CQCarson Quinn
Carson Quinn
PRPrashanth Rajarajan
Prashanth Rajarajan
AGAlexander J. Gill
Alexander J. Gill
HKHannah Kopinsky
Hannah Kopinsky
AWAndrew B. Wolf
Andrew B. Wolf
IKIlya Kister
Ilya Kister
Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with certain preexisting autoimmune diseases, and these patients may also experience exacerbation of the underlying autoimmune disease following ICI initiation. People with multiple sclerosis (MS) have mostly been excluded from clinical trials of ICIs, so data on the safety of ICIs in MS are limited. This study aims to assess the rate of MS activity, as well as neurologic and nonneurologic irAEs in persons with MS treated with ICIs for cancer. Participating sites were invited to this retrospective observational study through the Medical Partnership 4 MS+ listserv. Seven large academic centers participated in the study, each conducting a systematic search of their electronic medical record system for patients with MS and history of ICI treatment. The participating neurologist reviewed each chart individually to ensure the inclusion criteria were met. Demographics and data on MS and cancer history, treatments, and outcomes were abstracted from patient charts using a structured instrument. We identified 66 people with MS (median age 66 years, 73% female, 68% not on disease-modifying therapy for MS) who were treated with ICIs for lung cancer (35%), melanoma (21%), or another oncologic indication. During post-ICI follow-up (median: 11.7 months, range 0.2-106.3 months), 2 patients (3%) had relapse or MRI activity, 3 (5%) had neurologic irAEs, and 21 (32%) had nonneurologic irAEs. At the last follow-up, 25 (38%) participants had partial or complete remission of their cancer, while 35 (53%) were deceased. In this multi-institutional systematic retrospective study of predominantly older patients with MS, most of whom were not on disease-modifying therapy, MS activity and neurologic irAEs following ICI treatment were rare. These data suggest that preexisting MS should not preclude the use of ICIs for cancer in older patients, but the results may not be generalizable to younger patients with active MS. Prospective studies of ICI safety that enroll younger patients with MS are needed.

1 April 2022 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
BOBridget LaMonica Ostrem
Bridget LaMonica Ostrem
AAAnnika Anderson
Annika Anderson
SCSarah Conway
Sarah Conway
BHBrian C Healy
Brian C Healy
JOJiwon Oh
Jiwon Oh
MHMaria Houtchens
Maria Houtchens
Background: The effects of pregnancy on multiple sclerosis (MS) inflammatory activity are not well described in women with moderate to severe disabilities. Objective: To quantify the peripartum annualized relapse rate (ARR) in women with MS with an Expanded Disability Status Scale (EDSS) ≥ 3. Methods: We performed a retrospective cohort study of 85 pregnancies in 74 subjects with preconception EDSS ≥ 3. We quantified peripartum ARR and tested for risk factors predictive of peripartum relapses, postpartum brain magnetic resonance imaging activity (new T2 or gadolinium-enhancing lesions), and disability worsening. Results: There were 74 live births, with a 56% operative delivery rate. In subjects with relapsing-remitting MS, ARR decreased to 0.11 during the third trimester of pregnancy compared to 0.59 in the year preconception and increased to 1.22 in the 3 months postpartum. Women with a higher preconception EDSS had higher odds of postpartum relapses and clinically significant worsening of disability as compared to subjects with a lower EDSS. Conclusions: Moderately to severely disabled women with MS have a lower risk of relapse during pregnancy as compared to preconception, followed by a marked increase postpartum. Further studies are needed to identify ways to reduce peripartum inflammatory activity and disability progression in women with MS with moderate to severe disability.

7 June 2022 in Neurology
Verified
Journal Article
Open access
PDF file
SCSarah E. Conway
Sarah E. Conway
PVPavan A. Vaswani
Pavan A. Vaswani
JBJoshua A. Budhu
Joshua A. Budhu
LKLauren R. Kett
Lauren R. Kett
SESilviya H.M. Eaton
Silviya H.M. Eaton
SPSashank Prasad
Sashank Prasad
Appropriate parental leave policies remain an unmet need in graduate medical education. Although legal and institutional guidelines allow for policies that support parental leave, there are many challenges and perceived barriers to consider in developing and implementing a successful policy. In 2018, we revised the parental leave policy for our neurology residency. Here we describe the development of our policy, measure its effects, and offer guidelines for other programs to develop a similar approach. We propose solutions to commonly encountered problems, focusing on training and education, staffing of clinical services, evolving legal requirements, resident well-being and equity, and financial support.

2 July 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
KGKristin Galetta
Kristin Galetta
SRSophia Ryan
Sophia Ryan
GMGiovanna Manzano
Giovanna Manzano
LCLori B. Chibnik
Lori B. Chibnik
DBDenis Balaban
Denis Balaban
MMMarcelo Matiello
Marcelo Matiello